All Stories

  1. Cognitive resilience and improvements in health-related quality of life over 4 years in people with relapsing multiple sclerosis treated with cladribine tablets: Results from the CLARIFY-MS Extension study
  2. Italian guideline on palliative care in adult patients with grade 3/4 gliomas
  3. Quality of life domains revised by people with multiple sclerosis and healthcare professionals for adaptive measure development
  4. Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study
  5. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
  6. Advance care planning in multiple sclerosis (ConCure-SM): A multicenter single-arm pilot and feasibility study
  7. Healthcare for adults with long-term neurological conditions: European Academy of Neurology Members Survey
  8. Diagnostic delay and misdiagnosis of symptoms reported by patients with multiple sclerosis participating in a research registry
  9. Correction to: Neurology and physician-assisted suicide: position of the Italian society of neurology
  10. Neurology and physician-assisted suicide: position of the Italian society of neurology
  11. Neurology and physician-assisted suicide: glossary of definitions and terminology
  12. Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis—A systematic review and meta-analysis
  13. Education needs in palliative care and advance care planning of Italian residents in neurology: an online survey
  14. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
  15. Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study
  16. Italian cross-cultural adaptation of the Quality of Communication questionnaire and the 4-item advance care planning engagement questionnaire
  17. Italian cross-cultural adaptation of the patient-reported outcome measure of ataxia
  18. Patient and carer involvement in the formulation of research questions: findings from the Italian guideline on palliative care in adults with glioma
  19. Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis
  20. Health professional involvement in the formulation of research questions: findings from the Italian guideline on palliative care in adults with glioma
  21. Diagnosis concealment is prevalent in MS, and associated with diagnosis experience
  22. Motherhood choice in multiple sclerosis (MoMS) development and piloting of patient-reported outcome measures
  23. A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS)
  24. Cross-Country Adaptation of a Psychological Flexibility Measure: The Comprehensive Assessment of Acceptance and Commitment Therapy Processes
  25. Evaluation of a program for training psychologists in an acceptance and commitment therapy resilience intervention for people with multiple sclerosis: a single-arm longitudinal design with a nested qualitative study
  26. Advance Care Planning in Neurodegenerative Disorders: A Scoping Review
  27. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
  28. Correction to: Diagnosis and treatment of Chiari Malformation and syringomyelia in adults: International Consensus Document
  29. The development and use of the European academy of neurology guideline on palliative care in advanced progressive multiple sclerosis
  30. Construction of a resource for advance care planning in multiple sclerosis (ConCure-SM): Results of cognitive debriefing with users
  31. Involving patients and caregivers in the production of guidelines for palliative care in primary brain tumours: Identification of intervention priorities
  32. The management of Chiari malformation type 1 and syringomyelia in children: a review of the literature
  33. Viability of a MSQOL-54 general health-related quality of life score using bifactor model
  34. Effectiveness of a group resilience intervention for people with multiple sclerosis delivered via frontline services
  35. Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial
  36. Diagnosis and treatment of Chiari malformation and syringomyelia in adults: international consensus document
  37. Diagnosis and treatment of Chiari malformation type 1 in children: the International Consensus Document
  38. Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study
  39. The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system’s preparedness
  40. The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The “ImpACT-COVID-19 for Patients” Multi-Centre Observational Study
  41. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
  42. “I Will Respect the Autonomy of My Patient”
  43. 27th Annual Conference of the International Society for Quality of Life Research
  44. The impact of the face-to-face consultation on decisional conflict in complex decision-making in multiple sclerosis: A pilot study
  45. Implementation of a complex intervention to improve care for patients whose situations are clinically uncertain in hospital settings: A multi-method study using normalisation process theory
  46. Construction of a User-Led Resource for People Transitioning to Secondary Progressive Multiple Sclerosis: Results of an International Nominal Group Study
  47. Identifying Progression in Multiple Sclerosis: New Perspectives
  48. Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document
  49. Aggressive multiple sclerosis (1): Towards a definition of the phenotype
  50. Aggressive multiple sclerosis (2): Treatment
  51. Palliative care in multiple sclerosis: European guideline
  52. EAN guideline on palliative care of people with severe, progressive multiple sclerosis
  53. A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study
  54. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy
  55. Italian consensus on treatment of spasticity in multiple sclerosis
  56. 029 Importance of face-to-face consultation in complex decision-making
  57. Assessing measurement invariance of MSQOL-54 across Italian and English versions
  58. A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis
  59. Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany
  60. There is an urgent need for palliative care specialists in MS – Yes
  61. Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
  62. Author Correction: Multiple sclerosis
  63. Multiple sclerosis
  64. Information provision for people with multiple sclerosis
  65. Unmet needs of patients transitioning to secondary progressive multiple sclerosis: qualitative findings for a resource development
  66. THUR 172 Phase iv study of cladribine tablets and quality of life: clarify-ms
  67. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis
  68. Palliative care team consultation and quality of death and dying in a university hospital: A secondary analysis of a prospective study
  69. Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study
  70. eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54
  71. Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort
  72. [Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]
  73. What should a person with relapsing-remitting multiple sclerosis know? – Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0)
  74. Equivalence of the electronic versus paper-based short version of the MSQOL-54 (MSQOL-29)
  75. Managing the transition to secondary progressive multiple sclerosis: a scoping review
  76. Validity and reliability of multiple sclerosis quality of life-29 questionnaire in an english speaking cohort
  77. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A
  78. Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis
  79. Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy
  80. Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis
  81. Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres
  82. Erratum to: Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial
  83. Web-based medical and health information in multiple sclerosis: for patients and physicians
  84. Nerve conduction velocity in CMT 1A: what else can we tell?
  85. Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis
  86. Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories
  87. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory
  88. Erratum to: ‘Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial’
  89. Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions
  90. Development of a shortened version of the MSQOL-54 using factor analysis and item response theory
  91. Providing information for newly diagnosed people with multiple sclerosis
  92. Role preferences in treatment decisions of MS patients in Italy
  93. The ability to measure change of outcome measures in Charcot Marie Tooth neuropathy
  94. Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations
  95. Adherence to behavioural interventions in multiple sclerosis: Follow-up meeting report (AD@MS-2)
  96. Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial
  97. Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
  98. Adherence in multiple sclerosis (ADAMS): Classification, relevance, and research needs. A meeting report
  99. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients
  100. Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention
  101. Pain and small fiber function in charcot–marie–tooth disease type 1A
  102. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker
  103. Information provision for people with multiple sclerosis
  104. Is overwork weakness relevant in Charcot–Marie–Tooth disease?
  105. Effective communication at the point of multiple sclerosis diagnosis
  106. Use of Rasch analysis to refine a patient-reported questionnaire on satisfaction with communication of the multiple sclerosis diagnosis
  107. Implementation of the ‘Sapere Migliora’ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial
  108. Patient autonomy in multiple sclerosis — Possible goals and assessment strategies
  109. Authors’ response to Rahman and Fontes
  110. Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale
  111. Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments
  112. Vitamin C and Charcot–Marie–Tooth 1A: Pharmacokinetic considerations
  113. Self‐assessed health status changes in a community cohort of people with multiple sclerosis: 11 years of follow‐up
  114. Quality of life reporting in multiple sclerosis clinical trials: enough quality?
  115. Applying the theory of planned behaviour to multiple sclerosis patients’ decisions on disease modifying therapy – questionnaire concept and validation
  116. Health‐related quality of life and depressive symptoms in significant others of people with multiple sclerosis: a community study
  117. Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial
  118. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial
  119. Natalizumab for relapsing remitting multiple sclerosis
  120. Anxiety and depression in multiple sclerosis patients around diagnosis
  121. Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagement
  122. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial
  123. Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial
  124. Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
  125. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care
  126. Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis
  127. Methodological aspects of randomized controlled trials on cognitive interventions
  128. Idebenone: a guide to its use in Alzheimerʼs disease, other age-related cognitive disorders and Friedreichʼs ataxia
  129. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients
  130. Charcot–Marie–Tooth disease type 1A: is ascorbic acid effective?
  131. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study
  132. Accuracy of self-assessment of the minimal record of disability in patients with multiple sclerosis
  133. Natalizumab for relapsing remitting multiple sclerosis
  134. ERRATUM
  135. Participatory decision making in multiple sclerosis
  136. Participation in medical decision-making: Attitudes of Italians with multiple sclerosis
  137. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
  138. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease
  139. A shortened version of PASAT-3 is feasible
  140. Biological abnormalities of peripheral A2A receptors in a large representation of polyglutamine disorders and Huntington's disease stages
  141. Cognitive Profiles and Visuoperceptual Abilities in Preterm and Term Spastic Diplegic Children With Periventricular Leukomalacia
  142. Communicating the diagnosis of multiple sclerosis - a qualitative study
  143. Amantadine for fatigue in multiple sclerosis
  144. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
  145. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy
  146. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]
  147. Improvement in Quality of Life and Activity Limitations in Migraine Patients after Prophylaxis. A Prospective Longitudinal Multicentre Study
  148. A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others
  149. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis
  150. Mortality in Patients with a First Unprovoked Seizure
  151. Local drug delivery in recurrent malignant gliomas
  152. Role of health-related quality of life measures in the routine care of people with multiple sclerosis
  153. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
  154. The multiple sclerosis functional composite: different practice effects in the three test components
  155. Disability and quality of life in different primary headaches: results from Italian studies
  156. Disability in young patients suffering from primary headaches
  157. Measuring responses to therapy in headache patients: new and traditional end-points
  158. Corrigendum to “Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial” [J. Neurol. Sci. 222 (2004) 99–104]
  159. Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial
  160. General practitioners facing dementia: are they fully prepared?
  161. Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis
  162. Role of Gabapentin in Spinal Muscular Atrophy
  163. Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial
  164. Quality of life and disability in primary chronic daily headaches
  165. Health-Related Quality of Life in Patients with Cluster Headache During Active Periods
  166. Reliability of hand‐held dynamometry in spinal muscular atrophy
  167. Comparison of two brief neuropsychological batteries in people with multiple sclerosis
  168. Health status of people with multiple sclerosis: a community mail survey
  169. Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis
  170. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients
  171. Validation of Italian multiple sclerosis quality of life 54 questionnaire
  172. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients
  173. Detection of hereditary neuropathy with liability to pressure palsies among patients with acute painless mononeuropathy or plexopathy
  174. Incidence and survival of childhood CNS tumours in the Region of Lombardy, Italy
  175. Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients
  176. Relation of cognitive impairment and depression to quality of life in multiple sclerosis patients
  177. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy
  178. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion
  179. About Self-Assessment of Neurological Disability in Multiple Sclerosis
  180. Agreement in the Clinical Diagnosis of Dementia: Evaluation of a Case Series with Mild Cognitive Impairment
  181. A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results
  182. Interobserver Agreement in the Diagnosis of Multiple Sclerosis
  183. Classic Migraine – Clinical Findings in 164 Patients